I see this as a double win today for now and the l
Post# of 30066
(Total Views: 1057)
Posted On: 12/20/2021 8:27:45 AM
I see this as a double win today for now and the long term.
We are also very excited about working with iiiNTENT to drive growth for our Tollovir brand of products, as we believe that could be a big driver of revenue growth heading into 2022.”
Most recently, Mr. Valentino was the Omni-Channel Engagement Lead for Novartis Oncology where he developed media plans and led the execution of global digital solutions for Piqray’s early launch.
Indication
PIQRAY is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
https://www.hcp.novartis.com/products/piqray/...st-cancer/
About Todos Medical Ltd.
Todos completed the acquisition of U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos is focused on the commercialization of Videssa and will bring the TBIA tests to market thereafter.
We are also very excited about working with iiiNTENT to drive growth for our Tollovir brand of products, as we believe that could be a big driver of revenue growth heading into 2022.”
Most recently, Mr. Valentino was the Omni-Channel Engagement Lead for Novartis Oncology where he developed media plans and led the execution of global digital solutions for Piqray’s early launch.
Indication
PIQRAY is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
https://www.hcp.novartis.com/products/piqray/...st-cancer/
About Todos Medical Ltd.
Todos completed the acquisition of U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos is focused on the commercialization of Videssa and will bring the TBIA tests to market thereafter.
(0)
(0)